Acumen Pharmaceuticals, Inc. financial data

Symbol
ABOS on Nasdaq
Location
427 Park St., Charlottesville, VA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.72K % -22.4%
Debt-to-equity 17.9 % +367%
Return On Equity -33 % -38.3%
Return On Assets -28 % -21.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.1M shares +3.75%
Common Stock, Shares, Outstanding 60.1M shares +3.75%
Entity Public Float 134M USD -0.89%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.1M shares +10.8%
Weighted Average Number of Shares Outstanding, Diluted 60.1M shares +10.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 72.5M USD +82.3%
General and Administrative Expense 20.4M USD +19%
Operating Income (Loss) -92.9M USD -63.3%
Nonoperating Income (Expense) 11.2M USD +37.7%
Net Income (Loss) Attributable to Parent -81.7M USD -67.6%
Earnings Per Share, Basic -1.37 USD/shares -22.3%
Earnings Per Share, Diluted -1.37 USD/shares -22.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.2M USD -65%
Marketable Securities, Current 167M USD +38.7%
Other Assets, Current 457K USD +152%
Assets, Current 208M USD -5.02%
Property, Plant and Equipment, Net 89K USD -27.6%
Operating Lease, Right-of-Use Asset 296K USD +14700%
Other Assets, Noncurrent 170K USD -10.1%
Assets 267M USD -6.77%
Accounts Payable, Current 2.34M USD +72%
Employee-related Liabilities, Current 2.78M USD +35.2%
Accrued Liabilities, Current 4.93M USD +55.5%
Liabilities, Current 19.9M USD +227%
Operating Lease, Liability, Noncurrent 185K USD
Liabilities 49.8M USD +716%
Accumulated Other Comprehensive Income (Loss), Net of Tax 518K USD
Retained Earnings (Accumulated Deficit) -288M USD -39.6%
Stockholders' Equity Attributable to Parent 217M USD -22.5%
Liabilities and Equity 267M USD -6.77%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.9M USD -75.5%
Net Cash Provided by (Used in) Financing Activities 7.11M USD
Net Cash Provided by (Used in) Investing Activities -9.2M USD +78.1%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 60.1M shares +3.75%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.4M USD -64.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 756K USD
Deferred Tax Assets, Valuation Allowance 33.7M USD +52.2%
Deferred Tax Assets, Gross 34.1M USD +54%
Operating Lease, Liability 344K USD +228%
Depreciation 16K USD +14.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -80.6M USD -67%
Lessee, Operating Lease, Liability, to be Paid 388K USD
Operating Lease, Liability, Current 129K USD +6350%
Lessee, Operating Lease, Liability, to be Paid, Year Two 158K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 155K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 44K USD +1000%
Lessee, Operating Lease, Liability, to be Paid, Year Three 158K USD
Deferred Tax Assets, Operating Loss Carryforwards 16.6M USD +26.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 38K USD -5%
Additional Paid in Capital 505M USD +3.61%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 437K USD +1357%
Share-based Payment Arrangement, Expense 8.93M USD +65.3%
Interest Expense 1M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%